Skip to search formSkip to main contentSkip to account menu

ceritinib

Known as: céritinib, N-{2-[(5-chloro-2-{[2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}propane-2-sulfonamide, 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine 
An orally available inhibitor of the receptor tyrosine kinase activity of anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon… 
National Institutes of Health

Related topics

Related topics

9 relations

Broader (4)

Antineoplastic AgentsProtein Kinase InhibitorsPyrimidinesSulfones

Narrower (1)

LDK378
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase InhibitionReceptor Tyrosine Kinase Inhibitors [MoA]ceritinib 150 MG Oral Capsule [Zykadia]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
The efficacy and safety of ALK inhibitors in the treatment of ALK‐positive non‐small cell lung cancer: A network meta‐analysis
The current study was carried out to compare the effectiveness and safety of different ALK inhibitors in treating ALK+ NSCLC. 
Review
2018
Review
2018
Balancing early access with uncertainties in evidence for drugs authorized by prospective case series – systematic review of reimbursement decisions
To review clinical and cost‐effectiveness evidence underlying reimbursement decisions relating to drugs whose authorization… 
Review
2017
Review
2017
Treatment Patterns and Early Outcomes of ALK-Positive Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study
IntroductionThis study aimed to provide the first real-world description of the characteristics, treatments, dosing patterns, and… 
Review
2017
Review
2017
Treatment Paradigms for Advanced Non‐Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design
Selection of appropriate clinical endpoints for examining the efficacy of investigational agents for non‐small cell lung cancer… 
2017
2017
J-ALEX: alectinib versus crizotinib in ALK-positive lung cancer
2016
2016
Screening for ALK Rearrangements in Lung Cancer: Time for a New Generation of Diagnostics?
A study reported in this issue of The Oncologist examined the utility of next-generation sequencing (NGS) in detecting ALK… 
Review
2016
Review
2016
Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer ( NSCLC ) : updated results from…
Corresponding author: Dr Alice T Shaw, Massachusetts General Hospital, 32 Fruit Street, Boston, MA, 02114, Phone: 617 724 4000… 
2016
2016
Identification of I1171N resistance mutation in ALK-positive non-small-cell lung cancer tumor sample and circulating tumor DNA.
Review
2015
Review
2015
Future options for ALK-positive non-small cell lung cancer.
2015
2015
Phase I study of ceritinib in pediatric patients (Pts) with malignancies harboring a genetic alteration in ALK (ALK+): Safety, pharmacokinetic (PK), and efficacy results.
10005 Background: Ceritinib is a potent ALK inhibitor with durable efficacy in adult pts with ALK-translocated non-small cell… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)